Eli Lilly and Company $LLY Shares Sold by Linden Thomas Advisory Services LLC

Key Points

• Linden Thomas Advisory Services LLC reduced its stake in Eli Lilly by 36.6%, selling 2,849 shares, bringing its total holdings to 4,925 shares worth approximately $3.84 million.
• Despite the reduction in stake from some institutional investors, 82.53% of Eli Lilly's stock is still owned by institutional investors and hedge funds, indicating strong institutional support.
• Analysts have varied opinions on Eli Lilly's stock, with a consensus rating of "Moderate Buy" and an average price target of $938.61, reflecting differing expectations for future performance.

Linden Thomas Advisory Services LLC cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 36.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,925 shares of the company's stock after selling 2,849 shares during the period. Linden Thomas Advisory Services LLC's holdings in Eli Lilly and Company were worth $3,839,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Hobbs Wealth Management LLC grew its position in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC grew its position in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the period. Ascent Capital Management LLC grew its position in shares of Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the period. Finally, Willner & Heller LLC boosted its position in Eli Lilly and Company by 1.5% during the 1st quarter. Willner & Heller LLC now owns 854 shares of the company's stock worth $705,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective for the company. in a report on Sunday, August 17th. Finally, The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $938.61.

Eli Lilly and Company Stock Performance

LLY traded up $4.82 during trading hours on Friday, reaching $825.86. The company's stock had a trading volume of 2,207,377 shares, compared to its average volume of 3,510,202. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $781.65 billion, a PE ratio of 53.98, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company's 50-day moving average is $768.01 and its 200-day moving average is $768.14. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.